Inicio › Linfoma de células B › Texas › Houston
Ensayos clínicos de Linfoma de células B en Houston, TX
16 estudios para Linfoma de células B buscan participantes en centros de Houston y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
ReclutandoFase 3
- Md Anderson Cancer Center, Houston
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
ReclutandoFase 2
- MD Anderson Cancer Center, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
ReclutandoFase 1
- MD Anderson Cancer Center, Houston
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
ReclutandoFase 2
- M D Anderson Cancer Center, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
ReclutandoFase 2
- Research Site, Houston
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
ReclutandoFase 1/2
- The University of Texas Md Anderson Cancer Center, Houston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
ReclutandoFase 1/2
- Research Site, Houston
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
ReclutandoFase 1
- Clinical Trial Site, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
ReclutandoFase 1/2
- M D Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
ReclutandoFase 3
- MD Anderson Cancer Center, Houston
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
ReclutandoFase 1
- The University of Texas M D Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
ReclutandoFase 2
- The University of Texas MD Anderson Cancer Center, Houston
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
ReclutandoFase 1
- MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
ReclutandoEstudio observacional
- Texas Children's Hospital, Houston
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
ReclutandoFase 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
ReclutandoFase 1
- Texas Children's Hospital/Baylor College of Medicine, Houston
Ensayos de Linfoma de células B en otras ciudades
- New York City, NY19 estudios
- Chicago, IL12 estudios
- Nashville, TN11 estudios
- Philadelphia, PA11 estudios
- Rochester, MN10 estudios
- Milwaukee, WI9 estudios
- Baldwin Park, CA9 estudios
- Boston, MA8 estudios
- Cleveland, OH8 estudios
- Washington, DC7 estudios
- Denver, CO7 estudios
- Seattle, WA7 estudios
Otros estudios en Houston
- Cáncer de pulmón de células no pequeñas145 estudios
- Cáncer de seno126 estudios
- Cáncer (todos los tipos)122 estudios
- Cáncer metastásico104 estudios
- Cáncer del colon y del recto103 estudios
- Cáncer de ovario90 estudios
- Leucemia mielógena aguda86 estudios
- Cáncer de pulmón78 estudios
- Cáncer de próstata76 estudios
- Cáncer de endometrio69 estudios
- Cáncer de páncreas62 estudios
- Melanoma59 estudios
De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.